PAH
54 programs · 52 companies
Programs
54
Companies
52
Trials
51
MOAs
39
FGFRiMALT1iTYK2iAuroraAiALKiCD47iEGFRiVEGFiPI3KiFcRni
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Phase 3 | C5 | ||
| ABB-8985 | Phase 2 | CD20 | ||
| Zorisotorasib | Phase 1 | WRN | ||
| MRN-5715 | NDA/BLA | CDK4/6 | ||
| ALN-3284 | Phase 2/3 | CDK2 | ||
| Tirarapivir | Approved | SGLT2 | ||
| Mavuratamab | NDA/BLA | BET | ||
| RLA-8772 | Phase 2 | MALT1 | ||
| Tirasacituzumab | NDA/BLA | PI3Kα | ||
| Cevinaritide | Phase 3 | AuroraA | ||
| Zorizumab | Approved | CD123 | ||
| CSL-2468 | Phase 1/2 | LAG-3 | ||
| 460-4909 | Preclinical | PSMA | ||
| PEK-IIT-569 | Preclinical | PARP | ||
| MSK-IIT-346 | Phase 2 | ALK | ||
| SCO-5362 | NDA/BLA | USP1 | ||
| Miritinib | Approved | KIF18A | ||
| Elratenlimab | Phase 3 | CDK2 | ||
| Elrazanubrutinib | NDA/BLA | PLK4 | ||
| Talatuximab | Phase 1/2 | SHP2 | ||
| COR-899 | Phase 2/3 | DLL3 | ||
| Fixafotisoran | Phase 2/3 | TROP-2 | ||
| TUR-3071 | NDA/BLA | GIP-R | ||
| Suramavacamten | Phase 3 | WEE1 | ||
| Capibrutinib | Approved | TROP-2 | ||
| Niratuximab | Phase 1 | BTK | ||
| CLE-136 | Phase 3 | PARP | ||
| Terafutibatinib | Phase 2/3 | TYK2 | ||
| Bemarapivir | Approved | CD123 | ||
| NOR-4666 | Phase 3 | IL-13 | ||
| TRE-8359 | Preclinical | SMN2 | ||
| TRE-2745 | Phase 2/3 | EGFR | ||
| Olpasertib | Preclinical | MDM2 | ||
| Bemasotorasib | Phase 1/2 | GIP-R | ||
| Elralemzoparlimab | Phase 1/2 | IL-13 | ||
| 415-7410 | Phase 1 | MDM2 | ||
| LAU-4167 | NDA/BLA | AHR | ||
| NEO-5036 | Phase 1/2 | HER2 | ||
| SUP-4355 | Phase 2 | IL-17A | ||
| Daracilimab | Preclinical | TNFα | ||
| Poladerotide | Phase 3 | DLL3 | ||
| STA-4766 | Phase 1/2 | CD19 | ||
| Motaderotide | Phase 2 | C5 | ||
| Adagraratamab | Phase 1 | GPRC5D | ||
| TAB-3211 | Phase 3 | APOC3 | ||
| TAB-6074 | Preclinical | KRASG12C | ||
| CHA-IIT-901 | Approved | SMN2 | ||
| BRK-4512 | Preclinical | GIP-R | ||
| AVT-8949 | Phase 3 | KRASG12C | ||
| Sotozanubrutinib | Phase 2/3 | APOC3 | ||
| EWT-9686 | Phase 1 | TIGIT | ||
| ZHE-6042 | Phase 2 | FXIa | ||
| Voxazasiran | Phase 1 | PI3Kα | ||
| 115-7101 | Phase 1 | SGLT2 |
Trials (51)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT06895585 | LLY-9749 | Phase 3 | Active |
| NCT05380983 | ABB-8985 | Phase 2 | Completed |
| NCT04699747 | Zorisotorasib | Phase 1 | Terminated |
| NCT07278178 | Tirarapivir | Approved | Active |
| NCT04820807 | Mavuratamab | NDA/BLA | Active |
| NCT05018302 | RLA-8772 | Phase 2 | Active |
| NCT04735791 | Tirasacituzumab | NDA/BLA | Not yet recr... |
| NCT08627537 | Cevinaritide | Phase 3 | Completed |
| NCT05742107 | Zorizumab | Approved | Not yet recr... |
| NCT04905409 | Zorizumab | Approved | Recruiting |
| NCT08696892 | CSL-2468 | Phase 1/2 | Not yet recr... |
| NCT05664978 | 460-4909 | Preclinical | Recruiting |
| NCT07211877 | PEK-IIT-569 | Preclinical | Active |
| NCT07333308 | MSK-IIT-346 | Phase 2 | Completed |
| NCT07872588 | SCO-5362 | NDA/BLA | Not yet recr... |
| NCT06913381 | Miritinib | Approved | Active |
| NCT07976967 | Miritinib | Approved | Recruiting |
| NCT08283707 | Elratenlimab | Phase 3 | Completed |
| NCT03410549 | Elrazanubrutinib | NDA/BLA | Active |
| NCT07565348 | Elrazanubrutinib | NDA/BLA | Terminated |